Bill > HR5818

This bill, the Medicare IVIG Access Enhancement Act of 2023, aims to expand coverage of the in-home administration of intravenous immune globulin (IVIG) under the Medicare program. Specifically, it proposes to extend coverage for IVIG administration to individuals with chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), in addition to those with primary immune deficiency diseases. The bill also grants the Secretary of Health and Human Services the authority to vary the payment amounts for IVIG administration based on whether it is related to the treatment of primary immune deficiency, CIDP, or MMN.